What's New Related to Drugs
Updated Monday through Friday
- Current and Resolved Drug Shortages and Discontinuations Reported to FDA
- Drug Firm Annual Registration Status
- Drug Firm Annual Registration Status Download File
- National Drug Code Directory
- NDC Unfinished Drugs Excluded Database File
- NDC Database Excluded Packages and Products
- Wholesale Distributor and Third-Party Logistics Providers Reporting
Updated Weekly
Updated Biweekly
June 18, 2025
- FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
- Drug Trials Snapshots: REVUFORJ
- Drug Safety Communication: FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)
- Final Guidance: Post-Warning Letter Meetings Under GDUFA
June 17, 2025
June 13, 2025
- Orange Book
- Approved Drug Products with Therapeutic Equivalence Evaluations
- Orange Book Current Cumulative Supplement (updated)
- Additions/Deletions for Prescription and OTC Drug Product Lists (updated)
- Orange Book Data Files (compressed) (updated)
- Reference Listed Drugs by ANDA Reference Standard List (updated)
- Orange Book Patent Listing Dispute List (updated)
March 28, 2025
- FDA approves durvalumab for muscle invasive bladder cancer
- FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
March 26, 2025
- Helpful Webinars and Other Resources for Generic Drug Manufacturers
- FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
March 19, 2025
March 14, 2025
- Orange Book
- Approved Drug Products with Therapeutic Equivalence Evaluations
- Orange Book Current Cumulative Supplement (updated)
- Additions/Deletions for Prescription and OTC Drug Product Lists (updated)
- Orange Book Data Files (compressed) (updated)
- Reference Listed Drugs by ANDA Reference Standard List (updated)
- Orange Book Patent Listing Dispute List (updated)
March 11, 2025
March 7, 2025